Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation

[1]  Amy M. Sitapati,et al.  NCCN Guidelines Insights: Breast Cancer, Version 1.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  P. Lollini,et al.  Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug , 2013, PloS one.

[3]  Ying Jiang,et al.  Foxo3a Expression Is a Prognostic Marker in Breast Cancer , 2013, PloS one.

[4]  G. Stephanopoulos,et al.  Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. , 2013, Cancer research.

[5]  J. Ferlay,et al.  Global estimates of cancer prevalence for 27 sites in the adult population in 2008 , 2013, International journal of cancer.

[6]  M. Choti,et al.  Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  Edward Kai-Hua Chow,et al.  Mechanisms of chemoresistance in cancer stem cells , 2013, Clinical and Translational Medicine.

[8]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  David J. Chen,et al.  FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage , 2012, Nature Communications.

[10]  Richard J. Jones,et al.  Concise Review: Cancer Stem Cells and Minimal Residual Disease , 2012, Stem cells.

[11]  N. Nguyen,et al.  Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy , 2011, Journal of Translational Medicine.

[12]  S. Gygi,et al.  Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. , 2011, Molecular cell.

[13]  J. Schroeder,et al.  Understanding the Dual Nature of CD44 in Breast Cancer Progression , 2011, Molecular Cancer Research.

[14]  Shailendra Giri,et al.  Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. , 2011, Neoplasia.

[15]  I. Ellis,et al.  FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer , 2011, Breast Cancer Research and Treatment.

[16]  J. Campisi,et al.  DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion , 2011, Journal of Cell Science.

[17]  K. Nakayama,et al.  Inhibition of FOXO3 Tumor Suppressor Function by βTrCP1 through Ubiquitin-Mediated Degradation in a Tumor Mouse Model , 2010, PloS one.

[18]  I. Ben-Sahra,et al.  Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? , 2010, Molecular Cancer Therapeutics.

[19]  David A Hess,et al.  High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability , 2009, Journal of cellular and molecular medicine.

[20]  Peter G Schultz,et al.  Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4 , 2009, Proceedings of the National Academy of Sciences.

[21]  Chun Cheng,et al.  Low expression of Foxo3a is Associated with Poor Prognosis in Ovarian Cancer Patients , 2009, Cancer investigation.

[22]  T. Roberts,et al.  Simian Virus 40 Large T Antigen Disrupts Genome Integrity and Activates a DNA Damage Response via Bub1 Binding , 2008, Journal of Virology.

[23]  Katsuhiko Yano,et al.  FOXO3A genotype is strongly associated with human longevity , 2008, Proceedings of the National Academy of Sciences.

[24]  Xiao-Feng Sun,et al.  Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. , 2008, Oncology reports.

[25]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[26]  Zhaohui Xu,et al.  Functional interaction between FOXO3a and ATM regulates DNA damage response , 2008, Nature Cell Biology.

[27]  S. Gygi,et al.  The Energy Sensor AMP-activated Protein Kinase Directly Regulates the Mammalian FOXO3 Transcription Factor* , 2007, Journal of Biological Chemistry.

[28]  H. Nakauchi,et al.  Foxo3a is essential for maintenance of the hematopoietic stem cell pool. , 2007, Cell stem cell.

[29]  Yonghong Xiao,et al.  FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis , 2007, Cell.

[30]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[31]  W. Xia,et al.  Ionizing radiation activates expression of FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. , 2006, International journal of oncology.

[32]  W. Zong,et al.  Chemotherapeutic approaches for targeting cell death pathways. , 2006, The oncologist.

[33]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[34]  E. Greer,et al.  FOXO transcription factors at the interface between longevity and tumor suppression , 2005, Oncogene.

[35]  M. Goodarzi,et al.  Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents , 2005, Diabetes, obesity & metabolism.

[36]  C. Franceschi,et al.  Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice , 2005, Experimental Gerontology.

[37]  N. Motoyama,et al.  FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. , 2005, Antioxidants & redox signaling.

[38]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[39]  S. Nemoto,et al.  Nutrient Availability Regulates SIRT1 Through a Forkhead-Dependent Pathway , 2004, Science.

[40]  D. Pipeleers,et al.  Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. , 2004, Biochemical pharmacology.

[41]  Christopher J Bakkenist,et al.  Initiating Cellular Stress Responses , 2004, Cell.

[42]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[43]  Ryuji Kobayashi,et al.  IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a , 2004, Cell.

[44]  V. Triggiani,et al.  Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: role of hormones, growth factors and specific receptors. , 2004, Current drug targets. Immune, endocrine and metabolic disorders.

[45]  R. Coombes,et al.  FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines* , 2003, Journal of Biological Chemistry.

[46]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. R. Datta,et al.  DNA Repair Pathway Stimulated by the Forkhead Transcription Factor FOXO3a Through the Gadd45 Protein , 2002, Science.

[48]  C. Martínez-A,et al.  Forkhead transcription factors contribute to execution of the mitotic programme in mammals , 2001, Nature.

[49]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[50]  X. Ding,et al.  Prevention of pancreatic cancer induction in hamsters by metformin. , 2001, Gastroenterology.

[51]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[52]  P. Houghton,et al.  Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[54]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[55]  R. Hertzberg,et al.  Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. , 1989, Journal of medicinal chemistry.

[56]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[57]  C. M. Oslowski.  Stress Responses , 2015, Methods in Molecular Biology.

[58]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[59]  D. Troyer,et al.  Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo. , 2011, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[60]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.